




A TEXTBOOK OF COMPUTER AIDED DRUG DESIGN

Editors:

Dr. Kishor Danao
Dr. Deweshri Nandurkar

A TEXTBOOK OF COMPUTER AIDED DRUG DESIGN

Editors:

Dr. Kishor Danao

Assistant Professor

*Dadasaheb Balpande College
of Pharmacy, Nagpur,
Maharashtra*

Dr. Deweshri Nandurkar

Associate Professor

*Dadasaheb Balpande
College of Pharmacy,
Nagpur, Maharashtra*





Website: www.creativebooks.co.in

Email: creativebook11@gmail.com

Head Office: C-91/1 Yadav Nagar Samaypur Badli, Delhi - 110042

First Published by Creative Books 2025

Copyright © Creative Books

Title: A Textbook of Computer Aided Drug Design

ISBN: 978-81-968406-9-3

No part of this book may be reproduced or transmitted in any form whatsoever, electronic, or mechanical, including photocopying recording, or by any informational storage or retrieval system without the expressed written, dated and signed permission from the editor(s).

LIMITS OF LIABILITY/DISCLAIMER OF WARRANTY: The editor(s) and publisher of this book has used their best efforts in preparing this material. The editor(s) and publisher make no representation or warranties with respect to the accuracy, applicability, or completeness of the contents. They disclaim any warranties (expressed or implied), or merchantability for any particular purpose. The editor(s) and publisher shall in no event be held liable for any loss or other damages, including but not limited to special, incidental, consequential, or other damages. The information presented in this publication is compiled from sources and freely available on the internet believed to be accurate, however, both the publisher and editor(s) assume no responsibility for errors or omissions. The information in this publication is not intended to replace or substitute professional advice. The strategies outlined in this book may not be suitable for every individual, and are not meant to provide individualized advice or recommendations.

The advice and strategies found within may not be suitable for every situation. This work is sold with the understanding that neither the editor(s) nor the publisher is held responsible for the results accrued from the advice in this book. Nothing contained herein is to be constructed as medical advice.

All disputes are subject to Delhi jurisdiction only.

About Authors



Dr. Kishor R. Danao is 17 year of teaching experience in Dadasaheb Balpande College of Pharmacy, Nagpur, Maharashtra. He obtained his B. Pharm. and M. Pharm. from RTMNU, Nagpur in Pharmaceutical Chemistry. He has completed Ph. D. from Oriental University, Indore. Also, He has to his credit certified course in Drug Design & Patenting (DDP) from BII, India. He has published more than 36 research papers in national and international reputed journals. He has credited 3 books. He has published 13 chapter in cited books and also, 3 Indian patents in his credit. His interesting working area is on the computer aided drug design. He is life time member of APTI. His main interest & mission of life are to train students for better pharmacy career.



Dr. Deweshri Nandurkar is working as Associate Professor, Department of Pharmaceutical chemistry, Dadasaheb Balpande College of Pharmacy, Besa, Nagpur. She has completed her B. Pharm. from Department of Pharmaceutical Sciences, Nagpur University, Nagpur and M. Pharm. in Pharmaceutical Chemistry from Kamla Nehru College of Pharmacy, Butibori, Nagpur. Afterword's, she has completed her Ph. D. from Department of Pharmaceutical Sciences, Nagpur University, Nagpur. Her Research area of interest involves computer assisted rational designing and synthesis of various pharmacophores. She had published 20 research papers in National and International Journal. She has credited 5 chapters and 2 patents in her credit. She attended more than 25 national and international conferences. She is a life member of APTI, ACT and MSPC council. She received two gold medals for being University topper in M. Pharm. Pharmaceutical Chemistry branch 2012 examination. Her primary interest and aim in life are to prepare students for a successful pharmacy career.

Preface

We are pleased to introduce the first edition of ***“A Textbook of Computer Aided Drug Design”*** for Bachelor and Masters Pharmacy students, which is in accordance strictly with the syllabus of Pharmacy Council of India (PCI). The authors tried their best to present the book in a more illustrated manner, including up-to-date information on bioinformatics tools for the discovery and development of new drug molecules. Major objectives of this book is to provide a thorough background in those who want to explore themselves in the field of Computer Aided Drug Design. For better understanding, the book has been divided into 10 units. Unit 1 and 2 gives an insight into the introduction to drug discovery and development from traditional medicine and lead discovery. Unit 3 and 4 focusses on the analogue based drug design quantitative structure-activity relationship studies. Unit 5 and 6 integrates the knowledge of 3D QSAR. Unit 7 and 8 explains the knowledge of molecular docking and virtual screening techniques. Unit 9 and 10, the concept of molecular modelling and informatics.

Table of Contents

<i>Chapter 1: Drug Discovery and Development</i>	<i>1</i>
<i>Chapter 2: Lead Discovery</i>	<i>23</i>
<i>Chapter 3: Analog Based Drug Design</i>	<i>43</i>
<i>Chapter 4: Quantitative Structure Activity Relationship</i>	<i>67</i>
<i>Chapter 5: Physicochemical Parameters of QSAR</i>	<i>91</i>
<i>Chapter 6: 3D QSAR</i>	<i>107</i>
<i>Chapter 7: An Overview of Virtual Screening Techniques</i>	<i>131</i>
<i>Chapter 8: Molecular Docking</i>	<i>153</i>
<i>Chapter 9: Informatics and Methods in Drug Design</i>	<i>191</i>
<i>Chapter 10: Molecular Modelling</i>	<i>215</i>

Chapter 1

Drug Discovery and Development

*Sachin More, Rohini Kharwade, Krutika Sawarkar,
Kishor Danao*

*Dadasaheb Balpande College of Pharmacy, Nagpur,
Maharashtra-440037
smmore84@gmail.com

The process of bringing a new drug to market is complex and involves multiple stages, broadly categorized into drug discovery and drug development. While these terms are often used interchangeably, they refer to distinct phases of the pharmaceutical research and development (R&D) pipeline. This section delineates the differences between drug discovery and drug development, highlighting their objectives, methodologies, and key activities.

Drug Discovery

Identification of potential new drug candidates and validate their therapeutic potential is the key objective in drug discovery.

Key Activities involved in drug discovery are:

Target Identification and Validation:

Target Identification is identifying biological molecules (such as proteins, enzymes, or genes) that play a crucial role in a disease. Whereas, target validation means confirming that modulating the target has the desired therapeutic effect.

Hit Identification: Using automated techniques like High-Throughput Screening (HTS) to screen large libraries of compounds for activity against the target or employing computational methods

like virtual screening to predict which compounds might bind to the target.

Lead Generation and Optimization: Identifying promising compounds (hits) that show initial activity against the target is considered as lead generation.

Lead Optimization: Modifying chemical structures to improve potency, selectivity, and pharmacokinetic properties while reducing toxicity.

In Vitro and In Vivo Testing: In Vitro Testing evaluating the biological activity of compounds in cell-based assays and In Vivo Testing assessing the efficacy and safety of compounds in animal models of disease.

Structure-Activity Relationship (SAR) Analysis: Analyzing the relationship between chemical structure and biological activity to guide the design of more effective compounds.

Which facilitate in identification of one or more lead compounds that are ready for preclinical development.

Drug Development

To advance lead compounds through preclinical and clinical testing, regulatory approval, and ultimately to the market. Objective of drug development is bringing a new drug to market that is safe, effective, and manufactured to high-quality standards.

Key Activities involved in drug development are:

Preclinical Development:

Pharmacokinetics (PK) and Pharmacodynamics (PD) Studies: Assessing how the drug is absorbed, distributed, metabolized, and excreted (ADME) and its biological effects.

Toxicology Studies: Evaluating the potential adverse effects of the drug in animal models.

Formulation Development: Designing a suitable dosage form (e.g.,

pill, injection) for the drug.

Clinical Trials:

Phase I: Testing the drug's safety, tolerability, and pharmacokinetics in healthy volunteers or patients.

Phase II: Assessing the drug's efficacy and side effects in a larger group of patients with the target disease.

Phase III: Confirming the drug's efficacy and monitoring adverse reactions in a large, diverse patient population.

Phase IV: Conducting post-marketing surveillance to gather long-term safety and efficacy data after the drug is approved.

Regulatory Submission and Approval:

Investigational New Drug (IND) Application: Submitting preclinical data to regulatory authorities (e.g., FDA) to get approval for human trials.

New Drug Application (NDA) or Biologics License Application (BLA): Compiling all preclinical and clinical data, manufacturing information, and labeling proposals for regulatory review and approval.

Manufacturing and Scale-Up:

Developing large-scale manufacturing processes to produce the drug in sufficient quantities for clinical trials and commercial distribution.

Post-Market Surveillance:

Monitoring the drug's performance in the real world, identifying any rare or long-term side effects, and ensuring ongoing compliance with regulatory standards.

Target Identification and Validation

Target Identification

Target identification is a crucial first step in the drug discovery

process. It involves identifying a molecular target, typically a protein, gene, or RNA, that is associated with a disease and can be modulated by a drug to produce a therapeutic effect. Here are the key aspects and significance of target identification in drug discovery:

Importance of Target Identification

Foundation for Drug Development: The entire drug discovery process depends on correctly identifying a suitable target. A well-chosen target can lead to the development of effective and safe therapeutics.

Understanding Disease Mechanisms: Identifying targets helps researchers understand the underlying mechanisms of diseases. This knowledge can reveal how diseases develop and progress, and how they can be interrupted or reversed.

Efficiency and Cost-Effectiveness: Early and accurate target identification can streamline the drug discovery process, reducing time and costs. It helps in focusing resources on the most promising targets, thus avoiding wasted efforts on ineffective ones.

Reducing Risk of Failure: Drugs that are designed to interact with well-validated targets are more likely to succeed in clinical trials. Poor target selection is a common reason for drug failure in later stages.

Processes in Target Identification

High-Throughput Screening (HTS): HTS technologies are used to test large libraries of compounds against potential targets to identify those that have a desirable effect.

Bioinformatics and Systems Biology: Computational tools and databases help in predicting and identifying potential targets based on genetic, proteomic, and metabolic data.

Genomic Techniques: Techniques such as CRISPR-Cas9, RNA interference (RNAi), and gene knockout models are used to study gene function and validate targets.

Biomarkers: Identifying biomarkers associated with targets can aid in diagnosing diseases and monitoring the efficacy of therapies.

Collaborative Efforts: Collaboration between academia, industry, and clinical researchers is essential for the comprehensive identification and validation of targets. This often involves sharing data, resources, and expertise.

Significance of target identification in Drug Discovery

Biological Relevance: The identified target must have a clear and significant role in the disease. This ensures that modulating the target will have the desired therapeutic effect.

Drugability: The target should have properties that allow it to be modulated by small molecules or biologics. This includes having a binding site that a drug can interact with effectively.

Selectivity: The target should be specific to the disease to minimize off-target effects and reduce the risk of side effects. Selective targeting increases the likelihood of a safer drug profile.

Validation: Target validation involves confirming that modulating the target has the expected therapeutic effect. This is done through a combination of genetic, biochemical, and pharmacological approaches.

Challenges in Target Identification

Complexity of Biological Systems: The intricate and interconnected nature of biological pathways can make it difficult to identify and validate targets.

Target Validation: Even after a potential target is identified, extensive research is required to validate its role in the disease and its potential for being druggable.

Resistance Mechanisms: Diseases, particularly cancers and infectious diseases, can develop resistance to therapies, necessitating the identification of new targets.

Overall, successful target identification requires a multidisciplinary

approach, combining insights from molecular biology, genetics, pharmacology, and computational biology.

The first step in drug discovery is identifying a biological target, typically a protein, gene, or RNA that plays a crucial role in a disease process. Modern technologies, such as genomics, proteomics, and bioinformatics, have significantly enhanced our ability to identify and prioritize potential drug targets.

- **Genomics and Proteomics:** These technologies allow for the comprehensive study of genes and proteins, respectively, identifying those that are differentially expressed in diseased vs. healthy states.
- **Bioinformatics:** Computational tools and databases help analyze large datasets to identify potential targets and understand their biological functions.

Target Validation

Target validation is a critical step in the drug discovery process that confirms the role of a biological target in a disease and demonstrates that modulating this target can produce a therapeutic effect. Proper validation reduces the risk of failure in later stages of drug development and increases the chances of developing effective therapies. This section delves into the methodologies, importance, and challenges associated with target validation.

Importance of Target Validation

- **Establishing Biological Relevance:**
- Confirms that the target is directly involved in the disease mechanism.
- Ensures that the target's modulation can have a therapeutic effect on the disease.
- **Reducing Risk:**

- Mitigates the risk of late-stage failure by ensuring early that the target is viable.
- Saves time and resources by focusing efforts on validated targets.
- Informing Drug Development:
- Provides critical insights into the target's function and its interaction with potential drugs.
- Aids in the design of more effective and selective drug candidates.

Methodologies for Target Validation

Genetic Approaches

Knockout Models: Creating organisms (usually mice) with the target gene completely inactivated to study the resulting phenotype and disease progression.

Knockdown Models: Using RNA interference (RNAi) to reduce the expression of the target gene and observe the effects on the disease.

CRISPR-Cas9: Employing gene-editing technology to selectively modify or knock out target genes in various model systems.

Pharmacological Approaches

Small Molecule Inhibitors: Using known inhibitors to block the target's activity and assessing the impact on disease models.

Monoclonal Antibodies: Developing antibodies that specifically bind to the target and inhibit its function.

Chemical Probes: Designing highly selective probes that interact with the target to study its role in cellular processes.

Biochemical Approaches

Protein-Protein Interaction Studies: Investigating how the target interacts with other proteins and its role in cellular pathways.

Enzyme Activity Assays: Measuring the activity of the target enzyme in the presence and absence of potential modulators.

Omics Approaches

Transcriptomics: Analysing changes in gene expression profiles after modulating the target.

Proteomics: Studying changes in protein expression and post-translational modifications in response to target modulation.

Metabolomics: Examining alterations in metabolic pathways linked to the target's activity.

Animal Models

Disease Models: Using genetically engineered animals that replicate human disease conditions to study the effects of target modulation.

Xenograft Models: Implanting human tumor cells into immunocompromised mice to evaluate the impact of target modulation on tumor growth.

Cell-Based Assays

Reporter Gene Assays: Employing reporter genes to monitor the activity of the target pathway in response to drug candidates.

CRISPR Screens: Using CRISPR technology to knock out or modify the target gene in cell lines and observe the phenotypic effects.

Challenges in Target Validation

Complexity of Biological Systems

- Biological pathways are highly interconnected, making it difficult to attribute disease phenotypes to a single target.
- Compensatory mechanisms can mask the effects of target modulation.
- Relevance of Model Systems
- Differences between animal models and human biology can lead to discrepancies in target validation results.
- Ensuring that cell-based assays accurately reflect in vivo conditions is challenging.

Off-Target Effects

- Small molecules and genetic tools can have off-target effects, complicating the interpretation of results.
- Careful design and validation of tools are necessary to minimize off-target interactions.
- Redundancy and Robustness: Many biological systems have redundant pathways, so modulating one target may not produce a significant effect. Robust validation requires demonstrating that target modulation consistently affects the disease phenotype.

Once a potential target is identified, it must be validated to ensure its relevance to the disease. This involves demonstrating that modulation of the target (e.g., inhibition or activation) has a therapeutic effect.

- **Genetic Validation:** Techniques such as RNA interference (RNAi) or CRISPR/Cas9 can be used to knock down or edit the target gene to study its role in disease.
- **Pharmacological Validation:** Small molecules or biologics can be used to modulate the target's activity in cell-based or

animal models to assess therapeutic potential.

Lead Compound Identification and Optimization

High-Throughput Screening (HTS)

High-throughput screening involves testing thousands to millions of compounds for activity against the validated target. Automated robotic systems and sophisticated assays are employed to quickly identify “hits” that have desired biological activity.

- **Assay Development:** Designing robust and reliable assays is critical for successful HTS. Assays must be sensitive, specific, and reproducible.
- **Hit Identification:** Compounds that show activity in the primary screen are considered hits and undergo further validation and optimization.

Lead Optimization

Hits from HTS are optimized to improve their potency, selectivity, and pharmacokinetic properties. Medicinal chemists modify the chemical structure of hits to create lead compounds with enhanced therapeutic potential.

- **Structure-Activity Relationship (SAR) Studies:** Systematic modification of chemical structures to understand the relationship between molecular changes and biological activity.
- **In Silico Modeling:** Computational techniques to predict how modifications will affect the interaction between the compound and its target.

Preclinical Testing

Preclinical research is a crucial stage in drug discovery that occurs before clinical trials can begin. It involves a series of laboratory

tests and experiments using *in vitro* (test tube or cell culture) and *in vivo* (animal) models to gather data on the biological activity, safety, and efficacy of potential drug candidates. This chapter will provide an in-depth look into the various aspects of preclinical research, including its goals, methodologies, regulatory requirements, and challenges.

Goals of Preclinical Research

- **Assess Safety and Toxicity:** Determine the potential toxic effects of the drug candidate.
- Identify safe dosage ranges.
- Understand the compound's pharmacokinetics and pharmacodynamics.
- **Evaluate Efficacy:**
 - Confirm that the drug has the desired therapeutic effect.
 - Use relevant disease models to simulate human conditions.
- **Identify Pharmacokinetics (PK) and Pharmacodynamics (PD):**
- Study how the drug is absorbed, distributed, metabolized, and excreted (ADME).
- Analyze the relationship between drug concentration and its biological effect.
- **Optimize Lead Compounds:** Refine chemical structures to improve efficacy, reduce toxicity, and enhance drug-like properties.

Methodologies in Preclinical Research

In Vitro Studies: Cell Culture Models: Testing drug candidates on cell lines to assess cytotoxicity, mechanism of action, and

preliminary efficacy.

Biochemical Assays: Evaluating the interaction between the drug and its target at the molecular level.

In Vivo Studies: Animal Models: Using animals to study the drug's effects in a living organism. Commonly used models include mice, rats, and zebrafish.

Disease Models: Creating animal models that mimic human diseases to evaluate the therapeutic potential of the drug.

Pharmacokinetics (PK) Studies:

ADME Studies: Assessing how the drug is absorbed, distributed, metabolized, and excreted in animal models.

Bioavailability: Measuring the extent and rate at which the active drug reaches systemic circulation.

Pharmacodynamics (PD) Studies:

Dose-Response Relationships: Determining the relationship between the drug dose and its therapeutic effect.

Mechanism of Action: Understanding how the drug produces its effects at the target site.

Regulatory Requirements

- Good Laboratory Practice (GLP):
- Ensures the quality and integrity of non-clinical laboratory studies.
- Involves strict documentation, standard operating procedures (SOPs), and quality control measures.
- Toxicology Studies
- Acute Toxicity: Assessing the effects of a single dose to determine the lethal dose (LD50).

- **Chronic Toxicity:** Studying the effects of repeated doses over an extended period.
- **Carcinogenicity:** Evaluating the potential of the drug to cause cancer.
- **Genotoxicity:** Testing for DNA damage and mutations.
- **Reproductive Toxicity:** Assessing the effects on fertility and reproductive organs.

Investigational New Drug (IND) Application:

A regulatory submission to the FDA (or equivalent authorities) that includes preclinical data, manufacturing information, and clinical trial plans.

Approval of the IND application is required before beginning human clinical trials.

Challenges in Preclinical Research

Translational Gap:

Differences between animal models and human biology can lead to discrepancies in drug efficacy and safety. Efforts are ongoing to develop more predictive models, such as humanized mouse models and advanced in vitro systems.

Ethical Considerations:

The use of animals in research raises ethical concerns. Adherence to ethical guidelines and the 3Rs principle (Replacement, Reduction, Refinement) is essential. Alternatives to animal testing, such as organ-on-a-chip technologies, are being explored.

Complexity of Biological Systems:

The intricate nature of biological systems can make it challenging to predict drug behavior accurately. Comprehensive and well-designed studies are required to mitigate this complexity.

Cost and Time:

Preclinical research is resource-intensive, requiring significant investment in terms of time, money, and expertise. Streamlining processes and improving efficiency are ongoing goals in the field.

Clinical Trials

Clinical trials are the cornerstone of drug development, essential for determining the safety and efficacy of new therapeutic compounds. They involve a series of meticulously designed and regulated studies conducted in human subjects. This chapter will cover the phases of clinical trials, design considerations, regulatory requirements, ethical issues, and challenges faced in conducting these studies.

Phases of Clinical Trials

Clinical trials are typically divided into four phases, each with specific objectives and methodologies:

Phase I: Safety and Dosage: Assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of the drug in humans.

Design: Small group of healthy volunteers (20-100 participants).

Single ascending dose (SAD) or multiple ascending dose (MAD) studies to determine the maximum tolerated dose (MTD).

Key Assessments: Adverse events (AEs) and serious adverse events (SAEs).

PK parameters such as absorption, distribution, metabolism, and excretion (ADME).

Phase II: Efficacy and Side Effects: Evaluate the drug's efficacy and further assess its safety in a larger patient population.

Design: Larger group of patients (100-300 participants) with the target disease or condition.

Randomized controlled trials (RCTs) to compare the drug against

a placebo or standard treatment.

Key Assessments: Primary and secondary endpoints to measure efficacy.

Dose-response relationship and identification of optimal dosing regimens.

Monitoring of adverse effects and collection of additional safety data.

Phase III: Confirmation and Monitoring: Confirm the drug's efficacy, monitor side effects, and compare it with existing treatments.

Design: Large group of patients (300-3,000 participants).

Multicenter, double-blind, randomized controlled trials to ensure robust data.

Key Assessments: Comprehensive efficacy data to support regulatory approval.

Detailed safety profile to detect rare or long-term adverse effects.

Comparative effectiveness against current standard treatments.

Phase IV: Post-Market Surveillance: Monitor the drug's long-term effectiveness and safety after it has been approved and marketed.

Design: Post-marketing studies, including observational studies, registries, and additional RCTs if necessary.

Large, diverse patient populations in real-world settings.

Key Assessments: Long-term safety and efficacy data.

Detection of rare or late-onset adverse effects.

Assessment of the drug's performance in various subpopulations.

Clinical Trial Design

Randomisation and Blindness

Randomisation ensures that participants are assigned to treatment groups in a way that reduces bias. Can be basic, tiered, or blocked to balance critical features between groups.

Blinding: Single-blind: Only the participants are uninformed of their treatment assignment.

Double-blind: Neither subjects nor investigators are aware of the treatment assignment.

Triple-blind: Participants, investigators, and data analysts are all uninformed of the treatment assignment.

Inclusion and exclusion criteria

Inclusion Criteria: The characteristics that participants must possess in order to be eligible for the study (for example, a specified age range or disease stage).

Exclusion Criteria: Characteristics that disqualify participants from the study (for example, comorbid disorders or concurrent drugs).

Sample Size and Power

Sample size refers to the number of participants required to identify a statistically significant difference between treatment groups.

Power is the likelihood of correctly rejecting the null hypothesis when there is a true effect.

Statistical analysis

Intention-to-Treat (ITT) Analysis: Includes all participants as assigned, regardless of whether they followed the treatment procedure.

Per-procedure Analysis: Only includes participants who followed the procedure and completed the trial.

Safety Analysis: Examines safety data to identify adverse effects

and assess the overall risk-benefit balance.

Regulatory Requirements

Investigational New Drug (IND) Application: To obtain permission from regulatory authorities (e.g., FDA) to start clinical trials.

Components: Preclinical data, manufacturing information, and clinical trial protocols.

Safety data from animal studies and initial human dosing information.

Institutional Review Board (IRB) Approval: To ensure the protection of human subjects and the ethical conduct of clinical trials.

Components: Review of the study protocol, informed consent forms, and recruitment materials. Ongoing monitoring of trial conduct and participant safety.

Clinical Trial Registration: To increase transparency and avoid duplication of efforts.

Requirements: Registration of trials in public databases (e.g., ClinicalTrials.gov) before enrollment begins.

Disclosure of trial results upon completion.

New Drug Application (NDA) and Marketing Authorization: To obtain approval to market the drug based on evidence of safety, efficacy, and quality.

Components:

- Comprehensive data from preclinical and clinical studies.
- Manufacturing, labeling, and post-marketing surveillance plans.
- Ethical Considerations

- Informed Consent

Challenges in Clinical Trials

- Recruitment and Retention
- Difficulty finding eligible participants.
- High dropout rates due to lengthy study durations or adverse effects.
- Strategies:
 - Effective recruitment campaigns and patient engagement.
 - Providing support and incentives to retain participants.
- Complexity and Cost
- Resource Intensive:
 - Clinical trials require significant financial, logistical, and human resources.

Clinical trials are a vital component of drug discovery, providing the necessary evidence to ensure new therapies are safe and effective. Despite the challenges, advancements in technology, regulatory frameworks, and patient-centric approaches continue to improve the efficiency and success of clinical

Clinical trials are conducted in humans to evaluate the safety and efficacy of the drug candidate. They are typically divided into three phases.

In conclusion, the drug discovery and development process is a multifaceted journey involving scientific innovation, rigorous testing, and regulatory scrutiny. Despite its challenges, continued advancements in technology and methodology hold promise for more efficient and effective development of new therapies. Understanding the intricacies of this process is crucial for the advancement of medical science and the improvement of patient care.

This chapter provides a detailed overview of the drug discovery and development process, emphasizing the critical steps and challenges involved. It highlights the importance of each phase and the innovative approaches that are shaping the future of drug development.

References

1. DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003). "The price of innovation: new estimates of drug development costs." *Journal of Health Economics*, 22(2), 151-185. doi:10.1016/S0167-6296(02)00126-1
2. Hughes, J. P., Rees, S., Kalindjian, S. B., & Philpott, K. L. (2011). "Principles of early drug discovery." *British Journal of Pharmacology*, 162(6), 1239-1249. doi:10.1111/j.1476-5381.2010.01127.x
3. Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012). "Diagnosing the decline in pharmaceutical R&D efficiency." *Nature Reviews Drug Discovery*, 11(3), 191-200. doi:10.1038/nrd3681
4. Munos, B. (2009). "Lessons from 60 years of pharmaceutical innovation." *Nature Reviews Drug Discovery*, 8(12), 959-968. doi:10.1038/nrd2961
5. Kola, I., & Landis, J. (2004). "Can the pharmaceutical industry reduce attrition rates?" *Nature Reviews Drug Discovery*, 3(8), 711-715. doi:10.1038/nrd1470
6. Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010). "How to improve R&D productivity: the pharmaceutical industry's grand challenge." *Nature Reviews Drug Discovery*, 9(3), 203-214. doi:10.1038/nrd3078
7. Lindsay, M. A. (2003). "Target discovery." *Nature Reviews Drug Discovery*, 2(10), 831-838. doi:10.1038/nrd1202
8. Rask-Andersen, M., Masuram, S., & Schiöth, H. B. (2014). "The druggable genome: Evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication." *Annual Review of Pharmacology*

- and Toxicology, 54, 9-26. doi:10.1146/annurev-pharmtox-010611-134520
9. Bunnage, M. E. (2011). "Getting pharmaceutical R&D back on target." *Nature Chemical Biology*, 7(6), 335-339. doi:10.1038/nchembio.580
 10. Arrowsmith, J. (2011). "Trial watch: Phase II failures: 2008-2010." *Nature Reviews Drug Discovery*, 10(5), 328-329. doi:10.1038/nrd3439
 11. Hoelder, S., Clarke, P. A., & Workman, P. (2012). "Discovery of small molecule cancer drugs: Successes, challenges and opportunities." *Molecular Oncology*, 6(2), 155-176. doi:10.1016/j.molonc.2012.02.004
 12. Plenge, R. M., Scolnick, E. M., & Altshuler, D. (2013). "Validating therapeutic targets through human genetics." *Nature Reviews Drug Discovery*, 12(8), 581-594. doi:10.1038/nrd4051
 13. Schmidt, C. W. (2016). "Precision medicine: Paving the way for personalized healthcare." *Environmental Health Perspectives*, 124(10), A188-A195. doi:10.1289/ehp.124-A188
 14. Vamathevan, J., Birney, E., & Weinberg, R. A. (2019). "Applications of machine learning in drug discovery and development." *Nature Reviews Drug Discovery*, 18(6), 463-477. doi:10.1038/s41573-019-0021-6
 15. Crommelin, D. J., Bermejo, T., Bissig, M., de Vlieger, J. S., & Weert, M. V. (2011). "Pharmaceutical biotechnology: A new strategy for drug development." *European Journal of Pharmaceutical Sciences*, 43(4), 309-310. doi:10.1016/j.ejps.2011.07.010
 16. Hughes, J. P., Rees, S., Kalindjian, S. B., & Philpott, K. L. (2011). "Principles of Early Drug Discovery." *British Journal of Pharmacology*, 162(6), 1239-1249.
 17. DiMasi, J. A., Hansen, R. W., Grabowski, H. G. (2003). "The Drug Development Process: Step by Step" *Journal of Health Economics*, 22(2), 151-185.

18. Lipinski, C. A., Lombardo, F., Dominy, B. W., Feeney, P. J. (2001). "Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings" *Advanced Drug Delivery Reviews*, 46(1-3), 3-26.



A TEXTBOOK OF COMPUTER AIDED DRUG DESIGN



Dr. Kishor Danao



Dr. Deweshri Nandurkar

ABOUT THE BOOK

The “*A Textbook of Computer Aided Drug Design*” is intended for Bachelor and Masters Pharmacy students and is based on the syllabus of Pharmacy Council of India (PCI). The authors did their utmost to deliver the book in a more visually appealing manner.

This book provides up-to-date information on bioinformatics tools for the discovery and development of new drug molecules. It discusses a range of computational applications, including three-dimensional modelling of protein structures, protein-ligand docking, and molecular dynamics simulation of protein-ligand complexes for identifying desirable drug candidates. Moreover, it presents structure and ligand-based drug design tools to optimize known drugs and guide the design of new molecules. The book also describes methods for identifying small-molecule binding pockets in proteins, and summarizes the databases used to explore the essential properties of drugs, drug-like small molecules and their targets. In addition, the book highlights various tools to predict the absorption, distribution, metabolism, excretion (ADME) and toxicity (T) of potential drug candidate.

